Prespecified exploratory indirect comparison of SURPASS-CVOT (13,165) and 2,055 REWIND participants with type 2 diabetes and ASCVD: tirzepatide vs imputed placebo was associated with lower MACE-3 (HR 0.72) and all-cause death (HR 0.61).
RCTn = 15,220
Sattar et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND